Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells

References

• Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990–998.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Deininger MW, Eide CA, et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011;17:212–221.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Lipton JH. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk 2013;13:646–656.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–3412.
   PubMed Web of Science ®Google Scholar
• Goldman JM. Ponatinib for chronic myeloid leukemia. N Engl J Med 2012;367:2148–2149.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567–4576.
   PubMed Web of Science ®Google Scholar
• Shah NP. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Clin Adv Hematol Oncol 2011;9:925–926.
   PubMedGoogle Scholar
• Blangy A, Lane HA, d’Hérin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159–1169.
   PubMed Web of Science ®Google Scholar
• Dagenbach EM, Endow SA. A new kinesin tree. J Cell Sci 2004;117: 3–7.
   PubMed Web of Science ®Google Scholar
• Cochran JC, Sontag CA, Maliga Z, et al. Mechanistic analysis of the mitotic kinesin Eg5. J Biol Chem 2004;279:38861–38870.
   PubMed Web of Science ®Google Scholar
• Krzysiak TC, Gilbert SP. Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limitingATP hydrolysis. J Biol Chem 2006;281:39444–39454.
   PubMed Web of Science ®Google Scholar
• Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689–698.
   PubMed Web of Science ®Google Scholar
• Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67: 237–245.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak DH, Woessner R, et al. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 2009;23:1755–1762.
   PubMed Web of Science ®Google Scholar
• Hansen GM, Justice MJ. Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia. Oncogene 1999;18:6531–6539.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Jones SF, Williams DD, et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011;29:467–472.
   PubMed Web of Science ®Google Scholar
• Holen K, DiPaola R, Liu G, et al. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs 2012;30:1088–1095.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Garcia-Manero G, Borthakur G, et al. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 2012;118: 3556–3564.
   PubMed Web of Science ®Google Scholar
• Souid AK, Dubowy RL, Ingle AM, et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010;55: 1323–1328.
   PubMed Web of Science ®Google Scholar
• Holen KD, Belani CP, Wilding G, et al. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 2011;67:447–454.
   PubMed Web of Science ®Google Scholar
• Huszar D, Theoclitou M, Skolnik J, et al. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009;28:197–208.
   PubMed Web of Science ®Google Scholar
• La Rosée P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol 2010;47:335–343.
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Pruedhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003;40:80–82.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189–218.
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2013;28:525–542.
   PubMed Web of Science ®Google Scholar
• Tunquist BJ, Woessner RD, Walker DH. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther 2010;9:2046–2056.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Ishii H, Ogo N, et al. S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett 2010;298:99–106.
   PubMed Web of Science ®Google Scholar
• Song H, Zhou S, Wang R, et al. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy. ChemMedChem 2013;8:1736–1749.
   PubMed Web of Science ®Google Scholar